Skip to content
Hironao Wakabayashi, M.D., Ph.D.

Hironao Wakabayashi, M.D., Ph.D.

About Me

Professional Background

Hironao Wakabayashi earned M.D. after 6 year education at Fukushima Medical School in Japan on 1988. In the Department of Pathology (II) at Fukushima Medical School he enrolled Ph.D. program. He studied on cancer invasion and metastasis and earned Ph.D. at 1992. He obtained postdoctoral training ...
Hironao Wakabayashi earned M.D. after 6 year education at Fukushima Medical School in Japan on 1988. In the Department of Pathology (II) at Fukushima Medical School he enrolled Ph.D. program. He studied on cancer invasion and metastasis and earned Ph.D. at 1992. He obtained postdoctoral training at University of Texas MD Anderson Cancer Center in Huston working on the same subject until he had an appointment as a Research Assistant Professor at The Institute for Molecular Medicine at Irvine, CA on 1996. Since 1999 he has been working as a Research Assistant Professor in the Department of Biochemistry and Biophysics at University of Rochester studying on the structural and functional analyses of blood coagulation factor VIII.

Faculty Appointments

Research Assistant Professor - Department of Biochemistry and Biophysics (SMD)

Credentials

Post-doctoral Training & Residency

1992-1996 Postdoctoral Fellow,
Department of Tumor Biology The University of Texas M. D. Anderson Cancer Center, Houston, Texas, U.S.A. 1992 - 1996

Education

PhD | Japan-Fukushima Med Coll. Pathology. 1992

MD | Japan-Fukushima Med Coll. Medicine. 1988

Research

Structural and functional analyses of factor VIII

Factor VIII functions as a cofactor for the serine protease factor IXa in the surface-dependent conversion of zymogen factor X to the serine protease, factor Xa. Deficiency of factor VIII activity results in a marked reduction of factor IXa a...
Structural and functional analyses of factor VIII

Factor VIII functions as a cofactor for the serine protease factor IXa in the surface-dependent conversion of zymogen factor X to the serine protease, factor Xa. Deficiency of factor VIII activity results in a marked reduction of factor IXa activity and in the subsequent rates of factor Xa generated during the propagation phase of coagulation.
My research focuses on the role of metal ions for structural integrity and function of factor VIII. Active factor VIII can be reconstituted by combining the isolated subunits in the presence of Ca2+ or Mn2+. Ca2+ had little effect on inter-subunit affinity yet converted the inactive dimer to an active form. Alternatively, Cu2+ enhanced the inter-subunit affinity ~100-fold but yielded a dimer lacking cofactor activity. Site-directed mutagenesis is employed to identify residues important in Ca2+ binding to factor VIII and resultant effects of this binding on activity. Several acidic amino acids within segment 110-126 of the A1 domain of factor VIII that likely participate in the coordination of Ca2+ necessary for generation of maximal cofactor specific activity.

Recent Publications

Wakabayashi, H., Zhou, Q., Varfaj, F., and Fay, P. J.
A3 Domain Residue Glu1829 Contributes to A2 Subunit Retention in Factor VIIIa J. Thromb. Haemost., in press.

Varfaj, F., Neuberg, J., Jenkins, P. V., Wakabayashi, H., and Fay, P. J.
Role of P1 Arg in Activated Protein C - Catalyzed Inactivation of Factor VIIIa. Biochemical J. 396, 355-362, 2006.

Wakabayashi, H., Zhou, Q., Nogami#, K., Ansong, C., Varfaj, F., Miles, S., and Fay, P. J.
pH-dependent association of factor VIII chains: Enhancement of affinity at physiological pH by Cu2+. Biochim. Biophys. Acta 1764,1094-1101, 2006.

Nogami, K., Zhou, Q., Myles, T., Leung, L. L. , Wakabayashi, H., and Fay, P. J.
Exosite-interactive Regions in the A1 and A2 Domains of Factor VIII Facilitate Thrombin-catalyzed Cleavage of Heavy Chain.
J. Biol. Chem. 280, 18476-18487, 2005.

Nogami, K., Zhou, Q., Wakabayashi, H., and Fay, P. J. Thrombin-catalyzed activation of factor VIII with His substituted for Arg372 at the P1 site.
Blood 105, 4362-4368, 2005.

Wakabayashi, H., Su, Y. C. , Ahmad, S. S. , Walsh, P. N. , and Fay, P. J.
A Glu113Ala Mutation within a Factor VIII Ca(2+)-Binding Site Enhances Cofactor Interactions in Factor Xase.
Biochemistry 44, 10298-10304, 2005.

Nogami, K., Wakabayashi, H., Ansong, C., and Fay, P. J. Localization of a pH-dependent, A2 subunit-interactive surface within the factor VIIIa A1 subunit.
Biochim. Biophys. Acta 1701, 25-35, 2004.

Nogami, K., Freas, J., Manithody, C., Wakabayashi, H., Rezaie, A. R. , and Fay, P. J.
Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain.
J. Biol. Chem. 279, 33104-33113, 2004.

Nogami K., Lapan K.A., Zhou Q., Wakabayashi H., and Fay P.J.
Identification of a Factor Xa-interactive Site within Residues 337-372 of the Factor VIII Heavy Chain.
J. Biol. Chem. 279, 15763-15771, 2004.

Wakabayashi H., Freas J., Zhou Q., and Fay P.J.
Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity.
J. Biol. Chem. 279, 12677-12684, 2004.

Wakabayashi H., Zhen Z., Schmidt K.M., and Fay P.J.
Mn2+ binding to factor VIII Subunits and its effect on cofactor activity.
Biochemistry 42, 145-153, 2003.

Wakabayashi H., Schmidt K.M., and Fay P.J.
Ca2+ binding to both the heavy and light chains of factor VIII is required for cofactor activity.
Biochemistry 41, 8485-8492, 2002.

Wakabayashi H., Koszelak M., Mastri, M., and Fay P.J Metal-ion independent factor VIII subunit association and the role of calcium and copper for its affinity and activity.
Biochemistry 40, 10293-10300, 2001.

Patents

Recombinant Factor VIII Having Increased Specific Activity

Issue date: December 21, 2010

Patent #: 7,855,274

Country: United States

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Specific Activity

Issue date: October 07, 2010

Patent #: 2004296768

Country: Australia

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Specific Activity

Issue date: April 16, 2013

Patent #: 2,547,569

Country: Canada

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Specific Activity

Issue date: April 07, 2010

Patent #: 1699469

Country: Europe

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Stability

Issue date: December 25, 2012

Patent #: 8,338,571

Country: United States

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Specific Activity

Issue date: April 07, 2010

Patent #: GB1699469

Country: United Kingdom

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Specific Activity

Issue date: April 07, 2010

Patent #: DE1699469

Country: Germany

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Specific Activity

Issue date: April 07, 2010

Patent #: FR1699469

Country: France

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Stability

Issue date: September 03, 2014

Patent #: 2209908

Country: Europe

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Stability

Issue date: December 18, 2014

Patent #: 2008319183

Country: Australia

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Stability

Issue date: April 23, 2012

Patent #: MX298479

Country: Mexico

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Stability

Issue date: October 20, 2014

Patent #: 2531493

Country: Russia

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Stability

Issue date: November 28, 2012

Patent #: 2010/03049

Country: South Africa

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Enhanced Stability Following Mutation At the A1-C2 Domain Interface

Issue date: January 28, 2014

Patent #: 8,637,448

Country: United States

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Stability

Issue date: July 07, 2015

Patent #: 9,072,722

Country: United States

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Enhanced Stability Following Mutation At the A1-C2 Domain Interface

Issue date: October 21, 2014

Patent #: 8,865,154

Country: United States

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Stability

Issue date: September 03, 2014

Patent #: DE2209908

Country: Germany

Inventors: Philip J Fay, Hironao Wakabayashi

Recombinant Factor VIII Having Increased Stability

Issue date: September 03, 2014

Patent #: GB2209908

Country: United Kingdom

Inventors: Philip J Fay, Hironao Wakabayashi

Publications

Journal Articles

Specific length and structure rather than high thermodynamic stability enable regulatory mRNA stem-loops to pause translation.

Bao C, Zhu M, Nykonchuk I, Wakabayashi H, Mathews DH, Ermolenko DN

Nature communications.. 2022 February 2113 (1):988. Epub 02/21/2022.

Extending the Spacing between the Shine-Dalgarno Sequence and P-Site Codon Reduces the Rate of mRNA Translocation.

Wakabayashi H, Warnasooriya C, Ermolenko DN

Journal of molecular biology.. 2020 June 13 Epub 06/13/2020.

Author Correction: Transcriptional Regulation on Aneuploid Chromosomes in Diverse Candida albicans Mutants.

Tucker C, Bhattacharya S, Wakabayashi H, Bellaousov S, Kravets A, Welle SL, Myers J, Hayes JJ, Bulger M, Rustchenko E

Scientific reports.. 2019 July 59 (1):10019. Epub 07/05/2019.

and Genes of Opportunistic Human Pathogen Candida albicans Influence Echinocandin Susceptibility.

Suwunnakorn S, Wakabayashi H, Kordalewska M, Perlin DS, Rustchenko E

Antimicrobial agents and chemotherapy.. 2018 April 62 (4)Epub 03/27/2018.

Correction for Yang et al., "Tolerance to Caspofungin in Candida albicans Is Associated with at Least Three Distinctive Mechanisms That Govern Expression of Genes and Cell Wall Remodeling".

Yang F, Zhang L, Wakabayashi H, Myers J, Jiang Y, Cao Y, Jimenez-Ortigosa C, Perlin DS, Rustchenko E

Antimicrobial agents and chemotherapy.. 2018 April 62 (4)Epub 03/27/2018.

Transcriptional Regulation on Aneuploid Chromosomes in Divers Candida albicans Mutants.

Tucker C, Bhattacharya S, Wakabayashi H, Bellaousov S, Kravets A, Welle SL, Myers J, Hayes JJ, Bulger M, Rustchenko E

Scientific reports.. 2018 January 268 (1):1630. Epub 01/26/2018.

Correction to: NuA4 histone acetyltransferase activity is required for H4 acetylation on a dosage-compensated monosomic chromosome that confers resistance to fungal toxins.

Wakabayashi H, Tucker C, Bethlendy G, Kravets A, Welle SL, Bulger M, Hayes JJ, Rustchenko E

Epigenetics & chromatin.. 2017 November 710 (1):52. Epub 11/07/2017.

NuA4 histone acetyltransferase activity is required for H4 acetylation on a dosage-compensated monosomic chromosome that confers resistance to fungal toxins.

Wakabayashi H, Tucker C, Bethlendy G, Kravets A, Welle SL, Bulger M, Hayes J, Rustchenko E

Epigenetics & chromatin.. 2017 October 2310 (1):49. Epub 10/23/2017.

Tolerance to Caspofungin in Candida albicans Is Associated with at Least Three Distinctive Mechanisms That Govern Expression of Genes and Cell Wall Remodeling.

Yang F, Zhang L, Wakabayashi H, Myers J, Jiang Y, Cao Y, Jimenez-Ortigosa C, Perlin DS, Rustchenko E

Antimicrobial agents and chemotherapy.. 2017 May 61 (5)Epub 04/24/2017.

Chromosome 5 of Human Pathogen Candida albicans Carries Multiple Genes for Negative Control of Caspofungin and Anidulafungin Susceptibility.

Suwunnakorn S, Wakabayashi H, Rustchenko E

Antimicrobial agents and chemotherapy.. 2016 December 60 (12):7457-7467. Epub 11/21/2016.

Stabilizing interactions between D666-S1787 and T657-Y1792 at the A2-A3 interface support factor VIIIa stability in the blood clotting pathway.

Monaghan M, Wakabayashi H, Griffiths AE, Fay PJ

Journal of thrombosis and haemostasis : JTH.. 2016 May 14 (5):1021-30. Epub 03/21/2016.

Candida albicans Carriage in Children with Severe Early Childhood Caries (S-ECC) and Maternal Relatedness.

Xiao J, Moon Y, Li L, Rustchenko E, Wakabayashi H, Zhao X, Feng C, Gill SR, McLaren S, Malmstrom H, Ren Y, Quivey R, Koo H, Kopycka-Kedzierawski DT

PloS one.. 2016 11 (10):e0164242. Epub 10/14/2016.

Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.

Yada K, Nogami K, Takeyama M, Ogiwara K, Wakabayashi H, Shima M

Journal of thrombosis and haemostasis : JTH.. 2015 October 13 (10):1843-53. Epub 09/23/2015.

Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models.

Leong L, Sim D, Patel C, Tran K, Liu P, Ho E, Thompson T, Kretschmer PJ, Wakabayashi H, Fay PJ, Murphy JE

Blood.. 2015 January 8125 (2):392-8. Epub 10/20/2014.

Enhanced factor VIIIa stability of A2 domain interface variants results from an increased apparent affinity for the A2 subunit. Results from an increased apparent affinity for the A2 subunit.

Monaghan M, Wakabayashi H, Griffiths A, Wintermute J, Fay PJ

Thrombosis and haemostasis.. 2014 September 2112 (3):495-502. Epub 06/05/2014.

Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.

Kosloski MP, Shetty KA, Wakabayashi H, Fay PJ, Balu-Iyer SV

The AAPS journal.. 2014 September 16 (5):1038-45. Epub 06/17/2014.

Combining mutations that modulate inter-subunit interactions and proteolytic inactivation enhance the stability of factor VIIIa.

Wakabayashi H, Wintermute JM, Fay PJ

Thrombosis and haemostasis.. 2014 July 3112 (1):43-52. Epub 03/06/2014.

Cofactor activity in factor VIIIa of the blood clotting pathway is stabilized by an interdomain bond between His281 and Ser524 formed in factor VIII.

Wakabayashi H, Monaghan M, Fay PJ

The Journal of biological chemistry.. 2014 May 16289 (20):14020-9. Epub 04/01/2014.

Replacing the factor VIII C1 domain with a second C2 domain reduces factor VIII stability and affinity for factor IXa.

Wakabayashi H, Fay PJ

The Journal of biological chemistry.. 2013 October 25288 (43):31289-97. Epub 09/12/2013.

Modification of interdomain interfaces within the A3C1C2 subunit of factor VIII affects its stability and activity.

Wakabayashi H, Fay PJ

Biochemistry.. 2013 June 452 (22):3921-9. Epub 05/21/2013.

Molecular orientation of factor VIIIa on the phospholipid membrane surface determined by fluorescence resonance energy transfer.

Wakabayashi H, Fay PJ

The Biochemical journal.. 2013 June 1452 (2):293-301. Epub 1900 01 01.

The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.

Yada K, Nogami K, Wakabayashi H, Fay PJ, Shima M

Thrombosis and haemostasis.. 2013 June 109 (6):1007-15. Epub 03/07/2013.

Contribution of factor VIII light-chain residues 2007-2016 to an activated protein C-interactive site.

Takeyama M, Wakabayashi H, Fay PJ

Thrombosis and haemostasis.. 2013 February 109 (2):187-98. Epub 12/06/2012.

Sequences flanking Arg336 in factor VIIIa modulate factor Xa-catalyzed cleavage rates at this site and cofactor function.

Deangelis JP, Wakabayashi H, Fay PJ

The Journal of biological chemistry.. 2012 May 4287 (19):15409-17. Epub 03/12/2012.

Enhancing factor VIII and VIIIa stability by combining mutations at the A2 domain interface and A1-C2 domain interface.

Wakabayashi H, Griffiths AE, Fay PJ

Journal of thrombosis and haemostasis : JTH.. 2012 March 10 (3):492-5. Epub 1900 01 01.

Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase.

Takeyama M, Wakabayashi H, Fay PJ

Biochemistry.. 2012 January 2451 (3):820-8. Epub 01/17/2012.

The role of P4-P3' residues flanking Arg336 in facilitating activated protein C-catalyzed cleavage and inactivation of factor VIIIa.

Deangelis JP, Varfaj F, Wakabayashi H, Fay PJ

Thrombosis research.. 2011 November 128 (5):470-6. Epub 04/05/2011.

Increasing hydrophobicity or disulfide bridging at the factor VIII A1 and C2 domain interface enhances procofactor stability.

Wakabayashi H, Griffiths AE, Fay PJ

The Journal of biological chemistry.. 2011 July 22286 (29):25748-55. Epub 05/31/2011.

Membrane-binding properties of the Factor VIII C2 domain.

Novakovic VA, Cullinan DB, Wakabayashi H, Fay PJ, Baleja JD, Gilbert GE

The Biochemical journal.. 2011 April 1435 (1):187-96. Epub 1900 01 01.

Factor VIII lacking the C2 domain retains cofactor activity in vitro.

Wakabayashi H, Griffiths AE, Fay PJ

The Journal of biological chemistry.. 2010 August 13285 (33):25176-84. Epub 06/07/2010.

Combining mutations of charged residues at the A2 domain interface enhances factor VIII stability over single point mutations.

Wakabayashi H, Griffiths AE, Fay PJ

Journal of thrombosis and haemostasis : JTH.. 2009 March 7 (3):438-44. Epub 12/04/2008.

Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface.

Wakabayashi H, Varfaj F, Deangelis J, Fay PJ

Blood.. 2008 October 1112 (7):2761-9. Epub 07/23/2008.

Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa.

Wakabayashi H, Fay PJ

The Journal of biological chemistry.. 2008 April 25283 (17):11645-51. Epub 02/25/2008.

Residues surrounding Arg336 and Arg562 contribute to the disparate rates of proteolysis of factor VIIIa catalyzed by activated protein C.

Varfaj F, Wakabayashi H, Fay PJ

The Journal of biological chemistry.. 2007 July 13282 (28):20264-72. Epub 05/22/2007.

A3 domain residue Glu1829 contributes to A2 subunit retention in factor VIIIa.

Wakabayashi H, Zhou Q, Varfaj F, Fay PJ

Journal of thrombosis and haemostasis : JTH.. 2007 May 5 (5):996-1001. Epub 02/26/2007.

Role of P1 residues Arg336 and Arg562 in the activated-Protein-C-catalysed inactivation of Factor VIIIa.

Varfaj F, Neuberg J, Jenkins PV, Wakabayashi H, Fay PJ

The Biochemical journal.. 2006 June 1396 (2):355-62. Epub 1900 01 01.

pH-dependent association of factor VIII chains: enhancement of affinity at physiological pH by Cu2+.

Wakabayashi H, Zhou Q, Nogami K, Ansong C, Varfaj F, Miles S, Fay PJ

Biochimica et biophysica acta.. 2006 June 1764 (6):1094-101. Epub 04/22/2006.

A Glu113Ala mutation within a factor VIII Ca2+-binding site enhances cofactor interactions in factor Xase.

Wakabayashi H, Su YC, Ahmad SS, Walsh PN, Fay PJ

Biochemistry.. 2005 August 244 (30):10298-304. Epub 1900 01 01.

Thrombin-catalyzed activation of factor VIII with His substituted for Arg372 at the P1 site.

Nogami K, Zhou Q, Wakabayashi H, Fay PJ

Blood.. 2005 June 1105 (11):4362-8. Epub 02/10/2005.

Exosite-interactive regions in the A1 and A2 domains of factor VIII facilitate thrombin-catalyzed cleavage of heavy chain.

Nogami K, Zhou Q, Myles T, Leung LL, Wakabayashi H, Fay PJ

The Journal of biological chemistry.. 2005 May 6280 (18):18476-87. Epub 03/03/2005.

Localization of a pH-dependent, A2 subunit-interactive surface within the factor VIIIa A1 subunit.

Nogami K, Wakabayashi H, Ansong C, Fay PJ

Biochimica et biophysica acta.. 2004 September 11701 (1-2):25-35. Epub 1900 01 01.

Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain.

Nogami K, Freas J, Manithody C, Wakabayashi H, Rezaie AR, Fay PJ

The Journal of biological chemistry.. 2004 August 6279 (32):33104-13. Epub 05/27/2004.

Identification of a factor Xa-interactive site within residues 337-372 of the factor VIII heavy chain.

Nogami K, Lapan KA, Zhou Q, Wakabayashi H, Fay PJ

The Journal of biological chemistry.. 2004 April 16279 (16):15763-71. Epub 02/04/2004.

Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity.

Wakabayashi H, Freas J, Zhou Q, Fay PJ

The Journal of biological chemistry.. 2004 March 26279 (13):12677-84. Epub 01/13/2004.

Mechanisms of factor Xa-catalyzed cleavage of the factor VIIIa A1 subunit resulting in cofactor inactivation.

Nogami K, Wakabayashi H, Fay PJ

The Journal of biological chemistry.. 2003 May 9278 (19):16502-9. Epub 02/26/2003.

Altered interactions between the A1 and A2 subunits of factor VIIIa following cleavage of A1 subunit by factor Xa.

Nogami K, Wakabayashi H, Schmidt K, Fay PJ

The Journal of biological chemistry.. 2003 January 17278 (3):1634-41. Epub 11/07/2002.

Mn2+ binding to factor VIII subunits and its effect on cofactor activity.

Wakabayashi H, Zhen Z, Schmidt KM, Fay PJ

Biochemistry.. 2003 January 1442 (1):145-53. Epub 1900 01 01.

Ca(2+) binding to both the heavy and light chains of factor VIII is required for cofactor activity.

Wakabayashi H, Schmidt KM, Fay PJ

Biochemistry.. 2002 July 241 (26):8485-92. Epub 1900 01 01.

Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity.

Wakabayashi H, Koszelak ME, Mastri M, Fay PJ

Biochemistry.. 2001 August 2840 (34):10293-300. Epub 1900 01 01.

Cleavage of factor VIII heavy chain is required for the functional interaction of a2 subunit with factor IXA.

Fay PJ, Mastri M, Koszelak ME, Wakabayashi H

The Journal of biological chemistry.. 2001 April 13276 (15):12434-9. Epub 01/22/2001.

Cancer cell heparanase activity associated with invasion and metastasis.

Nicolson GL, Nakajima M, Wakabayashi H, Boyd DD, Diaz D, Irimura T

Advances in enzyme regulation.. 1998 38 :19-32. Epub 1900 01 01.

Differential motility stimulation but not growth stimulation or adhesion of metastatic human colorectal carcinoma cells by target organ-derived liver sinusoidal endothelial cells.

Sawada H, Wakabayashi H, Nawa A, Mora E, Cavanaugh PG, Nicolson GL

Clinical & experimental metastasis.. 1996 May 14 (3):308-13. Epub 1900 01 01.

Responses to paracrine chemotactic and autocrine chemokinetic factors and lung metastatic capability of mouse RAW117 large-cell lymphoma cells.

Wakabayashi H, Cavanaugh PG, Nicolson GL

British journal of cancer.. 1994 December 70 (6):1089-94. Epub 1900 01 01.

Cell surface laminin-like substances and laminin-related carbohydrates of rat ascites hepatoma AH7974 and its variants with different lung-colonizing potential.

Kawaguchi T, Ono T, Wakabayashi H, Igarashi S

Clinical & experimental metastasis.. 1994 May 12 (3):203-12. Epub 1900 01 01.

Substrate adhesiveness and experimental metastatic potential of rat ascites hepatoma AH7974-derived variant sublines.

Kawaguchi T, Igarashi S, Wakabayashi H, Yokoya S, Fukui K

Clinical & experimental metastasis.. 1992 July 10 (4):225-38. Epub 1900 01 01.

Microcirculation disturbance in malignant neoplasms.

Kawaguchi, T., Sugino, T., and Wakabayashi, H.

Biomedicine and Therapeutics. 1992; 26: 19-23.

Two autopsy cases of primary leiomyosarcoma of the liver. Superiority of muscle-specific actin immunoreactivity in diagnosis.

Watanabe K, Saito A, Wakabayashi H, Kawaguchi T, Suzuki T

Acta pathologica japonica.. 1991 June 41 (6):461-5. Epub 1900 01 01.

Expression of fibronectin and laminin of tumor cells with different substratum adhesiveness and experimental metastatic potential.

Kawaguchi, T., Ono, T., Sakuma, A., Igarashi, S., Wakabayashi, H., and Yokoya, S.

Igaku-no-Ayumi. 1990; 152: 113-114.

Expression of laminin and laminin carbohydrates and metastatic potential of tumor cells.

Kawaguchi, T., Ono, T., Igarashi, S., and Wakabayashi, H.

Medical English. 1990; 7: 4-6.

Books

Cell Biology: A laboratory Handbook (1998)

Chapter: Transfilter cell invasion assays

Authors: Wakabayashi, H. and Nicolson G. L.

Publisher: Academic press, San Diego 1998

Cell Culture Handbook (1993)

Chapter: Determination of invasive ability into Matrigel or Collagen.

Authors: Wakabayashi, H.

Publisher: Chugain Igaku Co., Tokyo, Japan 1993